Strategic partnerships Leverage past and potential collaborations with Laborie Medical Technologies and ClinLogix to explore co-development, distribution, or licensing deals for the Optilume drug-coated balloon technology in urology markets and adjacent applications.

Capital and growth The company has raised multiple rounds including a $15M Series C and earlier $20M Series B, signaling investor confidence. This suggests capacity for scaled manufacturing, clinical trials, and expanded sales efforts; position partnerships that align with capital deployment or milestone-based collaborations.

Market need BPH and urethral strictures affect a large aging male population. Emphasize sales conversations around minimally invasive treatment advantages, potential to capture share from traditional methods, and alignment with urology practices seeking improved patient outcomes and workflow efficiency.

Sales enablement With a small internal team (11-50 employees), there is an opportunity to offer turnkey sales support, clinical education, and training programs for distributors and hospitals to accelerate adoption and physician acceptance of Optilume technology.

Competitive positioning Highlight differentiation from conventional treatments and position as a paradigm shift in urology. Target strategic accounts via health systems and large urology groups, emphasizing outcomes, reduced invasiveness, and potential cost benefits to drive procurement interest.